GSK J4 (GSK-J4) is a novel, cell permeable, and potent prodrug of GSK J1 with anti-inflammatory effects.

GSK2807 TFA (GSK-2807 TFA), the trifluoroacetic acid salt form of GSK2807, is a selective and SAM-competitive SMYD3 inhibitor with potential antitumor activity.

Pulrodemstat (formerly CC-90011; LSD1-IN-7; CC90011) is a novel, highly potent, reversible and orally bioavailable inhibitor of lysine specific demethylase-1 (LSD1) with anticancer activity.

PBIT is a novel Inhibitor of Jumonji AT-rich Interactive Domain 1B (JARID1B) Histone Demethylase.

SP2509 (HCI2509) is a novel, potent and selective histone demethylase LSD1 (KDM1A) antagonist with antineoplastic activity.

GSK-690 hydrochloride is a selective reversible inhibitor of lysine specific demethylase 1 (LSD1) with anticancer activity.

KDM5-C70 is a novel and potent JARID1 (Jumonji AT-Rich Interactive Domain 1) Histone Demethylases Inhibitor with anticancer activity.

CBB-1007 is a novel and potent Lysine-specific demethylase 1 (LSD1) inhibitor (IC50 = 5.27 μM for hLSD1) with anticancer activity.

T-3775440 (T3775440) HCl is a novel, potent, selective, and irreversible lysine-specific histone demethylase (LSD1) inhibitor with anticancer activity.

Furazolidone is a nitrofuran derivative with potent antiprotozoal and antibacterial activity.